Mortality rate due to heart diseases increases dramatically with age. Captopril is an angiotensin
converting enzyme inhibitor (ACE) used effectively for the management of hypertension. Due
to short elimination half-life of captopril the oral dose is very high. Captopril is prone to oxidation and
it has been reported that the oxidation rate of captopril in skin tissues is considerably low when compared
to intestinal tissues. All these factors make captopril an ideal drug candidate for transdermal delivery.
In this research work an effort was made to formulate transdermal films of captopril by utilizing
polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA) as film formers and polyethylene glycol 400 (PEG400) as a
plasticizer. Dimethyl sulfoxide (DMSO) and dimethylformamide (DMF) were used as permeation enhancers. Physicochemical
parameters of the films such as appearance, thickness, weight variation and drug content were evaluated. The invitro
permeation studies were carried out through excised human cadaver skin using Franz diffusion cells. The in-vitro
permeation studies demonstrated that the film (P4) having the polymer ratio (PVP:PVA = 80:20) with DMSO (10%) resulted
a promising drug release of 79.58% at 24 hours with a flux of 70.0 µg/cm2/hr. No signs of erythema or oedema
were observed on the rabbit skin as a result of skin irritation study by Draize test. Based on the stability report it was confirmed
that the films were physically and chemically stable, hence the prepared films are very well suited for transdermal
Keywords: Transdermal, captopril, dimethyl formamide, dimethylsulfoxide, polyvinyl alcohol, polyvinylpyrrolidone.
Rights & PermissionsPrintExport